ID   4Z-B-1
AC   CVCL_B7D6
DR   CCRID; 4201PAT-CCTCC01847
DR   Wikidata; Q112926992
RX   PubMed=34141711;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202123.
CC   Population: Chinese.
CC   Characteristics: ER-negative, PR-negative and ERBB2-positive (PubMed=34141711).
CC   Doubling time: 40 hours (PubMed=34141711).
CC   Karyotypic information: Nearly triploid (PubMed=34141711).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=34141711
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 9
ST   D16S539: 10
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=34141711; DOI=10.3389/fcell.2021.680968; PMCID=PMC8204809;
RA   Li Z.-Q., Zhuo W.-Y., Chen L.-N., Zhang X., Chen C., Hu D.-D.,
RA   Chen Y.-X., Yang J.-J., Zhou Y.-L., Mao M.-S., Xu L., Ju S.-W.,
RA   Shen J., Wang Q.-C., Dong M.-J., Xie S.-D., Zhou J.-C., Wang L.-B.;
RT   "Establishment and characterization of a HER2-positive cell line
RT   derived from the pleural effusion of a drug-resistant breast cancer
RT   patient.";
RL   Front. Cell Dev. Biol. 9:680968.1-680968.13(2021).
//